{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:54:37Z","timestamp":1788447277180,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/bf03346732","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T19:08:43Z","timestamp":1397156923000},"page":"876-880","source":"Crossref","is-referenced-by-count":48,"title":["Dose of intravenous steroids and therapy outcome in Graves\u2019 orbitopathy"],"prefix":"10.1007","volume":"34","author":[{"given":"S.","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. A.","family":"Ponto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"Kahaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,27]]},"reference":[{"key":"BF03346732_CR1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMcp0806317","volume":"360","author":"L Bartalena","year":"2009","unstructured":"Bartalena L, Tanda ML. Clinical practice. Graves\u2019 ophthalmopathy. N Engl J Med 2009, 360: 994\u20131001.","journal-title":"N Engl J Med"},{"key":"BF03346732_CR2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N Engl J Med 2010, 362: 726\u201338.","journal-title":"N Engl J Med"},{"key":"BF03346732_CR3","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C. Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev. 2000, 21: 168\u201399.","journal-title":"Endocr Rev."},{"key":"BF03346732_CR4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1210\/jc.2010-2329","volume":"96","author":"L Bartalena","year":"2011","unstructured":"Bartalena L. The dilemma of how to manage Graves\u2019 hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 2011, 96: 592\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346732_CR5","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1210\/jc.2005-1553","volume":"90","author":"L Bartalena","year":"2005","unstructured":"Bartalena L. Editorial: glucocorticoids for Graves\u2019 ophthalmopathy: how and when. J Clin Endocrinol Metab 2005, 90: 5497\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346732_CR6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson A, et al; European Group on Graves\u2019 Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008, 158: 273\u201385.","journal-title":"Eur J Endocrinol"},{"key":"BF03346732_CR7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","volume":"18","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of Graves\u2019 orbitopathy. Thyroid 2008, 18: 333\u201346.","journal-title":"Thyroid"},{"key":"BF03346732_CR8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ajo.2011.02.018","volume":"152","author":"KA Ponto","year":"2011","unstructured":"Ponto KA, Hommel G, Pitz S, Elflein H, Pfeiffer N, Kahaly GJ. Quality of life in a German Graves\u2019 Orbitopathy population. Am J Ophthalmol 2011, 152: 483\u201390.","journal-title":"Am J Ophthalmol"},{"key":"BF03346732_CR9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011, 96: 320\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346732_CR10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/187152211795495689","volume":"11","author":"S Zang","year":"2011","unstructured":"Zang S, Kahaly GJ. Steroids and the immune response in Graves\u2019 orbitopathy. Immunol Endocr Metab Agents Med Chem 2011, 11: 90\u20138.","journal-title":"Immunol Endocr Metab Agents Med Chem"},{"key":"BF03346732_CR11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/thy.2010.1640","volume":"20","author":"KA Ponto","year":"2010","unstructured":"Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves\u2019 orbitopathy. Thyroid 2010, 20: 785\u201393.","journal-title":"Thyroid"},{"key":"BF03346732_CR12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343835","volume":"24","author":"PE Macchia","year":"2001","unstructured":"Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G. High-dose intravenous corticosteroid therapy for Graves\u2019 ophthalmopathy. J Endocrinol Invest 2001, 24: 152\u20138.","journal-title":"J Endocrinol Invest"},{"key":"BF03346732_CR13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1034\/j.1600-0420.2002.800316.x","volume":"80","author":"R Kauppinen-M\u00e4kelin","year":"2002","unstructured":"Kauppinen-M\u00e4kelin R, Karma A, Leinonen E, et al. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroidassociated ophthalmopathy. Acta Ophthalmol Scand 2002, 80: 316\u201321.","journal-title":"Acta Ophthalmol Scand"},{"key":"BF03346732_CR14","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral glucocorticoid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 2005, 90: 5234\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346732_CR15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","volume":"61","author":"S Aktaran","year":"2007","unstructured":"Aktaran S, Akarsu E, Erbagci I, Araz M, Okumus S, Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy. Int J Clin Pract 2007, 61: 45\u201351.","journal-title":"Int J Clin Pract"},{"key":"BF03346732_CR16","first-page":"3562","volume":"86","author":"C Marcocci","year":"2001","unstructured":"Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001, 86: 3562\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346732_CR17","first-page":"322","volume":"11","author":"CM Ng","year":"2005","unstructured":"Ng CM, Yuen HK, Choi KL, et al. Combined orbital irradiation and systemic glucocorticoids compared with systemic glucocorticoids alone in the management of moderate-to-severe Graves\u2019 ophthalmopathy: a preliminary study. Hong Kong Med J 2005, 11: 322\u201330.","journal-title":"Hong Kong Med J"},{"key":"BF03346732_CR18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","volume":"63","author":"IM Wakelkamp","year":"2005","unstructured":"Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a firstline treatment of optic neuropathy in Graves\u2019 ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005, 63: 323\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03346732_CR19","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1210\/jc.2006-1800","volume":"92","author":"F Menconi","year":"2007","unstructured":"Menconi F, Marin\u00f2 M, Pinchera A, et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves\u2019 orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 2007, 92: 1653\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346732_CR20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-07-0558","volume":"158","author":"RJ Geest van","year":"2008","unstructured":"van Geest RJ, Sasim IV, Koppeschaar HP, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol 2008, 158: 229\u201337.","journal-title":"Eur J Endocrinol"},{"key":"BF03346732_CR21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1530\/acta.0.1160513","volume":"116","author":"Y Nagayama","year":"1987","unstructured":"Nagayama Y, Izumi M, Kiriyama T, et al. Treatment of Graves\u2019 ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol (Copenh) 1987, 116: 513\u20138.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"BF03346732_CR22","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1136\/bmj.297.6663.1574","volume":"297","author":"P Kendall-Taylor","year":"1988","unstructured":"Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M, Hall K. Intravenous methylprednisolone in the treatment of Graves\u2019 ophthalmopathy. BMJ 1988, 297: 1574\u20138.","journal-title":"BMJ"},{"key":"BF03346732_CR23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1507\/endocrj.40.63","volume":"40","author":"Y Hiromatsu","year":"1993","unstructured":"Hiromatsu Y, Tanaka K, Sato M, et al. Intravenous methylprednisolone pulse therapy for Graves\u2019 ophthalmopathy. Endocr J 1993, 40: 63\u201372.","journal-title":"Endocr J"},{"key":"BF03346732_CR24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1507\/endocrj.43.689","volume":"43","author":"T Tagami","year":"1996","unstructured":"Tagami T, Tanaka K, Sugawa H, et al. High-dose intravenous glucocorticoid pulse therapy in thyroid-associated ophthalmopathy. Endocr J 1996, 43: 689\u201399.","journal-title":"Endocr J"},{"key":"BF03346732_CR25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-978843","volume":"30","author":"G Matejka","year":"1998","unstructured":"Matejka G, Verg\u00e8s B, Vaillant G, et al. Intravenous methylprednisolone pulse therapy in the treatment of Graves\u2019 ophthalmopathy. Horm Metab Res 1998, 30: 93\u20138.","journal-title":"Horm Metab Res"},{"key":"BF03346732_CR26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0021-5155(02)00544-0","volume":"46","author":"K Ohtsuka","year":"2002","unstructured":"Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves\u2019 ophthalmopathy. Jpn J Ophthalmol 2002, 46: 563\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"BF03346732_CR27","first-page":"158","volume":"60","author":"G Kulig","year":"2009","unstructured":"Kulig G, Andrysiak-Mamos E, Sowi\u00f1ska-Przepiera E, et al. Quality of life assessment in patients with Graves\u2019 disease and progressive infiltrative ophthalmopathy during combined treatment with methylprednisolone and orbital radiotherapy. Endokrynol Pol 2009, 60: 158\u201365.","journal-title":"Endokrynol Pol"},{"key":"BF03346732_CR28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1089\/jop.2005.21.328","volume":"21","author":"RH Hart","year":"2005","unstructured":"Hart RH, Kendall-Taylor P, Crombie A, Perros P. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J Ocul Pharmacol Ther 2005, 21: 328\u201336.","journal-title":"J Ocul Pharmacol Ther"},{"key":"BF03346732_CR29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/01676830903104728","volume":"28","author":"A Mensah","year":"2009","unstructured":"Mensah A, Vignal-Clermont C, Chadi M, et al. Dysthyroid optic neuropathy: atypical initial presentation and persistent visual loss. Orbit 2009, 28: 354\u201362.","journal-title":"Orbit"},{"key":"BF03346732_CR30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/thy.1994.4.409","volume":"4","author":"H Koshiyama","year":"1994","unstructured":"Koshiyama H, Koh T, Fujiwara K, Hayakawa K, Shimbo S, Misaki T. Therapy of Graves\u2019 ophthalmopathy with intravenous highdose glucocorticoid followed by orbital irradiation. Thyroid 1994, 4: 409\u201313.","journal-title":"Thyroid"},{"key":"BF03346732_CR31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1055\/s-0028-1128141","volume":"41","author":"I Sterker","year":"2009","unstructured":"Sterker I, Tegetmeyer H, Papsdorf K, F\u00fchrer-Sakel D. Effect of combined intravenous glucocorticoids and orbital radiotherapy in restoring driving competency in patients with Graves\u2019 orbitopathy. Horm Metab Res 2009, 41: 391\u20136.","journal-title":"Horm Metab Res"},{"key":"BF03346732_CR32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9394(02)01970-0","volume":"135","author":"K Ohtsuka","year":"2003","unstructured":"Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves\u2019 ophthalmopathy. Am J Ophthalmol 2003, 135: 285\u201390.","journal-title":"Am J Ophthalmol"},{"key":"BF03346732_CR33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","volume":"156","author":"M Salvi","year":"2007","unstructured":"Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007, 156: 33\u201340.","journal-title":"Eur J Endocrinol"},{"key":"BF03346732_CR34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1575-0922(09)70841-1","volume":"56","author":"R S\u00e1nchez-Ortiga","year":"2009","unstructured":"S\u00e1nchez-Ortiga R, Moreno-P\u00e9rez O, Gonz\u00e1lez S\u00e1nchez V, et al. Treatment of Graves\u2019 ophthalmopathy with highdose intravenous methylprednisolone: a comparison of two dosing regimens. Endocrinol Nutr 2009, 56: 118\u201322.","journal-title":"Endocrinol Nutr"},{"key":"BF03346732_CR35","doi-asserted-by":"crossref","unstructured":"Marcocci C, Watt T, Altea MA, et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves\u2019 orbitopathy: a questionnaire survey among members of the Europaen Thyroid Association. Eur J Endocrinol 2011, Nov 4 [E-pub ahead of print]; doi: 10.1530\/EJE-11-0779.","DOI":"10.1530\/EJE-11-0779"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03346732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03346732\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03346732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T11:48:12Z","timestamp":1565351292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03346732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["BF03346732"],"URL":"https:\/\/doi.org\/10.1007\/bf03346732","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}